A2 functional diversity through mRNA splicing Flashcards

1
Q

how many introns does the average human gene have and what size are they

A

8 but some have >100
from 50 to 10,000 nts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what does the cap on pre-mRNA involve

A

involves methylation of bases
and formation of rare 5’ to 5’ triphosphate bridge with GTP
occurs when pre-mRNA is around 25 nt long
involves specific capping proteins
enhances stability and is key for efficient translation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what does the Poly(A) tail on pre-mRNA involve

A

Poly A added by enzyme called poly(A) polymerase
(A)n where n may be 250+
increases stability and enhances translation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what do all introns start and end with

A

start with GU and with AG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is the key to splicing introns

A

a pyrimidine rich tract (PY)n and a specific adenine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

splicing proteins recognise specific sites, what are these

A

the GU at the 5’ splice site and the branch site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

the proteins involved in splicing recruit other proteins into the large complex called what

A

spliceosome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what can the spliceosome do

A

can capture, splice, and release RNA accurately and in a coordinated way which involves a careful choreography of spliceosome components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is alternative splicing

A

a process whereby different mRNAs are generated from the same initial (primary) transcript

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what can cause disease by affecting splicing

A

mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what can happen when splicing goes awry

A

formation of a non functional protein or mutated one

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how can some RNA mols self splice

A

because RNA can fold into distinct structures it has the capacity to act as an enzyme and splice itself

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what drives splicing within the RNA structure

A

short stretches of nts on RNA can bp with other regions creating folds which in turn drives splicing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

who discovered that RNA can act as an enzyme and self splice

A

tom cech and sidney altman

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is RNA interference

A

RNAi is a powerful tool to disrupt gene expression
discovered when double stranded RNA was introduced into a cell
found to suppress the transcription of genes that contained sequences present in the original double stranded RNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what does RNAi reply on

A

key activity of small interfering RNAs (or siRNAs)

17
Q

what is RNAi widely used in SIPBS for

A

to silence the expression of specific genes

18
Q

why is RNAi exploited in cell biology

A

to examine the function of a particular gene product by silencing other genes

19
Q

what is the name given to genome editing

A

CRISPR/Cas

20
Q

technology behind CRISPR/CAs

A

specific guide gRNA is synthesised that directs an endonuclease enzyme called Cas( to specific DNA target sequence
can be used to create a cleavage in the DNA at a precise point and so insert or delete nucleotides (or create a frameshift)

21
Q

what are the potential uses or CRISPR

A

-poweful lab tool to create cell lines to probe specific gene function by creating a ‘knockout’
-can produce specific mutations in the germ line- probe function of key putative residues in a protein
-can be used ex vivo and in vivo genome editing for clinical therapy

22
Q

ex vivo genome editing for clinical therapy

A

cells isolated from a patient to be treated
edited then regrafted back to patient
to achieve therapeutic success, the target cells must be able to survive in vitro ad=nd return to the target tissue after transplantation

23
Q

in vivo genome editing for clinical therapy

A

engineered nucleases are delivered by viral or nonviral approached and directly injected into the patient for systemic or targeted tissues (ie eye, brain, or muscle) effect